Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Wegovy Manufacturing Issues Continue To Hamper Novo Nordisk

Aug 03 2022

• By Joseph Haas

Novo Nordisk — Novo Nordisk continues to win GLP-1 market share in diabetes

Related Content

Novo’s Wegovy Excels But Lilly Rival Hot On Heels

Apr 29 2022

Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise

May 13 2022

Tirzepatide’s Glowing Obesity Data Steal Show On Lilly’s Earnings Call

Apr 28 2022

Related Companies

Novo Nordisk A/S

Eli Lilly and Company

Additional Topics

Sales & Earnings Business Strategies Commercial Metabolic Disorders BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window